Listed on
(Coverage)
JCR2013-2023
SJR2013-2020;2022-2023
CiteScore2012-2023
SCIE2013-2024
SCOPUS2017-2024
MEDLINE2021-2024
DOAJ2020-2024
EMBASE2016-2024
OA Info.
| OA |
oa mark
based on the information
- 2020;2021;2022;2023;2024;2025;
|
| Keywords |
oncology, immunology, immunotherapy, tumour immunology |
| Review Process |
Anonymous peer review |
Journal info.
pages |
|
| Licences |
CC BY, CC BY-NC |
| Copyrights |
No |
| DOAJ Coverage |
Added on Date : 2020-05-11T11:24:01Z |
| Subject(s) |
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy | Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
Country
USA
Aime & Scopes
Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. This high-profile journal, OncoImmunology specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.
OncoImmunology accepts high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses are welcome.
